Challenge
As a clinical-stage biotechnology company, Vera Therapeutics needed to clearly communicate complex scientific advancements—particularly the latest 96-week data from the ORIGIN trial and the updated mechanism of action (MOA) for their lead candidate, atacicept—to investors, clinicians, and key opinion leaders.

Science Story™
With new, positive ORIGIN trial results and an evolved understanding of how atacicept works in IgA nephropathy, Vera’s messaging had to explain the science in a way that fostered confidence and understanding with both clinical and non-clinical audiences.

Activation
We produced a series of updated educational videos highlighting atacicept’s MOA and showcasing the most recent ORIGIN trial data. These visually engaging tools made the science accessible and impactful for stakeholders.

Results
The videos successfully supported Vera’s marketing and communications goals for atacicept by building understanding, enhancing confidence, aiding investment discussions, and helping engage clinicians and the medical community.